title: Field evaluation of WHO-MDT of fixed duration, at ALERT, Ethiopia: the AMFES project--II. Reaction and neuritis during and after MDT in PB and MB leprosy patients.
abstract: For a cohort of 286 leprosy patients the incidence rates and clinical manifestations of leprosy reactions during treatment and surveillance are described. Currently, individual patients had been observed for up to 4 years. It is intended that surveillance within this project should continue for up to 5 years after treatment. Of 128 PB patients, observed for 267 person-years (mean 2.1) 27 had 35 episodes of reaction, corresponding to an overall incidence rate of 131 events per 1000 person-years-at-risk (pyar). Of 158 MB patients observed for 402 person years (mean 2.5), 64 had 114 reactions, with an overall incidence of 284 events per 1000 pyar. For both PB and MB patients, incidence rates during treatment and post-MDT surveillance were similar. For PB patients, pre-existing physical impairment at the start of MDT was a significant risk factor for the occurrence of subsequent events, but this was not found in MB patients.
authors.affiliation: All Africa Leprosy Rehabilitation and Training Centre (ALERT), Addis Ababa, Ethiopia.
authors.forename: A J
authors.initials: AJ
authors.lastname: de Rijk
authors.forename: S
authors.initials: S
authors.lastname: Gabre
authors.forename: P
authors.initials: P
authors.lastname: Byass
authors.forename: T
authors.initials: T
authors.lastname: Berhanu
mesh_terms: D016001:Confidence Intervals; D004185:Disability Evaluation; D004359:Drug Therapy, Combination; D005002:Ethiopia / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D007917:Leprostatic Agents / Q000627:therapeutic use*; D007918:Leprosy / Q000150:complications* / Q000188:drug therapy* / Q000453:epidemiology; D009443:Neuritis / Q000209:etiology* / Q000503:physiopathology; D009460:Neurologic Examination; D011314:Preventive Health Services; D012882:Skin Tests; D014944:World Health Organization
chemical_list: D007917:Leprostatic Agents